Shots:

• Sandoz to get commercialization rights for Rizmoic (naldemedine) in Germany- UK and the Netherlands with rights of first refusal for other European markets. Shionogi will be responsible for Rizmoic’s manufacturing & development
• The focus of the agreement is to enhance Sandoz's anti-pain portfolio for minimizing the side-effects of opioid use in Europe
• Rizmoic (naldemedine-0.2mg) is an oral peripherally-acting mu-opioid receptor antagonist (PAMORA) and has received EU marketing authorization on Feb 22- 2019

Ref: Sandoz | Image: Behance